Bulletin from Moberg Pharma´s Extraordinary General Meeting on 3 May 2022

Report this content

STOCKHOLM, 3 May 2022. Moberg Pharma AB (publ)’s (OMX: MOB) (“Moberg Pharma” or the “Company”) Extraordinary General Meeting took place today. The Extraordinary General Meeting resolved as set out below.

Approval of the Board of Directors decision on a rights issue
The Extraordinary General Meeting resolved to approve the Board of Directors’ resolution on 8 April 2022 to issue ordinary shares with preferential rights for the current shareholders in the Company. According to the terms for the rights issue determined by the Board of Directors, as announced on 8 April 2022, each share in the Company held on the record date for participation in the rights issue, 11 May 2022, entitles to one (1) subscription right and eight (8) subscription rights entitle to subscription for nine (9) new ordinary shares. In aggregate, up to 52,516,260 new ordinary shares may be issued, entailing an increase in the share capital of a maximum of SEK 5,251,626.

The subscription price is SEK 2.30 per ordinary share. The Company is expected to receive issue proceeds of approximately SEK 121 million before transaction costs. The subscription period will run during the period 13 May 2022 – 27 May 2022, or such later date as decided by the Board of Directors. Additional information regarding the rights issue will be included in the prospectus which is expected to be published on 11 May 2022.

For additional information, please contact:
Anna Ljung, CEO, telephone: 070 - 766 60 30, e-mail: anna.ljung@mobergpharma.se

Mark Beveridge, VP Finance, telephone: 076 - 805 82 88, e-mail: mark.beveridge@mobergpharma.se

About this information
The information was submitted for publication, through the agency of the contact persons set out above, at 11:00 CEST on 3 May 2022.

About Moberg Pharma, www.mobergpharma.se
Moberg Pharma AB (publ) is a Swedish pharmaceutical company focused on commercializing proprietary innovations based on drug delivery of proven compounds. The Company’s main asset, MOB-015, is a novel topical treatment for onychomycosis. Data from phase 3 clinical trials in more than 800 patients for MOB-015 indicate that the product has the potential to become the future market leader in onychomycosis. Moberg Pharma has agreements with commercial partners in place in Europe and Japan, among others, and the Company's goal is to receive its first market approval and launch MOB-015 in 2023. Moberg Pharma is headquartered in Stockholm and the Company’s shares are listed on the Small Cap list of the Nasdaq Stockholm (OMX: MOB).